Group items tagged

Susan Rienow, UK Managing Director and Country President of Pfizer is all set to take up her role as President of the Association of the British Pharmaceutical Industry (ABPI). The association had announced her appointment in March. Last year in September she was appointed as the vice-president of ABPI. In her new role, she will oversee the ABPI, the ABPI Board, and the ABPI's Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA). Susan takes up the Presidency as negotiations begin for a new Voluntary Scheme for branded medicines pricing between the government, NHS England and the ABPI. All parties are looking to secure a new agreement that will help improve patient outcomes, support a healthier population and a financially sustainable NHS, while also supporting economic growth for the UK.

The Royal Pharmaceutical Society (RPS) Wales and the Association of the British Pharmaceutical Industry (ABPI) co-hosted a drop-in session to inform members of the Senedd (MSs) about the action taken by pharmacists to make medicines use more sustainable. At a 'drop-in' session the ABPI, RPS members and staff had the opportunity to speak to a number of MSs from all political parties. "With medicines accounting for around 25 per cent of the NHS carbon emissions, conversations were based around the key recommendations to reverse this from the RPS' policies on sustainability," said RPS. The three key themes emphasised in all discussions were- the need to educate the public and change behaviours to avoid stockpiling medicines; How the clinical skills of prescribing pharmacists can be used for appropriate de-prescribing and switching patients to low carbon options; and importance of tackling waste. RPS Wales Director Elen Jones said: "It was fantastic to see how interested and engaged the politicians were around these important issues. By the end of our conversations, they all clearly understood and supported the importance of pharmacy leadership in this area, as well as the need for the link between climate change and medicines to be better understood by patients.

The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll. This trend appears to be persisting with the study showing a generally favourable view of the sector. The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians. The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field. Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.